Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain

The discovery of therapeutic monoclonal antibodies (mAbs) primarily focuses on their biological activity favoring the selection of highly potent drug candidates. These candidates, however, may have physical or chemical attributes that lead to unfavorable chemistry, manufacturing, and control (CMC) p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:MAbs
Hauptverfasser: Bauer, Joschka, Mathias, Sven, Kube, Sebastian, Otte, Kerstin, Garidel, Patrick, Gamer, Martin, Blech, Michaela, Fischer, Simon, Karow-Zwick, Anne R
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2020
Schlagworte:
Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7531517/
https://ncbi.nlm.nih.gov/pubmed/32658605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2020.1787121
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge